Drug Profile
RDEA 427
Alternative Names: RDEA427Latest Information Update: 18 Jul 2018
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Ardea Biosciences
- Class Antiretrovirals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections